GlassScriptPhysician profile
Prianka Sinha
NPI 1831502160
$1,435.00
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $152 · 2021: $262 · 2022: $111.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $312.73 | 2019 | |
| Ironshore Pharmaceuticals INC. | $299.07 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.85 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $160.89 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $120.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $80.61 | 2019 | |
| Supernus Pharmaceuticals, INC. | $64.22 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $40.81 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $36.00 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $29.31 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $23.41 | 2021 | |
| Lundbeck LLC | $18.16 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.68 | 2020 | |
| Shire North American Group INC | $12.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prianka Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.